Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication.

Bezinelli LM, Eduardo FP, Migliorati CA, Ferreira MH, Taranto P, Sales DB, Santi CG, Macarenco RS, Godoy CPV, Corrêa L, Buzaid AC.

J Immunother. 2019 Nov/Dec;42(9):359-362. doi: 10.1097/CJI.0000000000000280.

PMID:
31246641
2.

Management of metastatic cutaneous melanoma: updates in clinical practice.

Schvartsman G, Taranto P, Glitza IC, Agarwala SS, Atkins MB, Buzaid AC.

Ther Adv Med Oncol. 2019 May 22;11:1758835919851663. doi: 10.1177/1758835919851663. eCollection 2019. Review.

3.

Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers.

Hyams DM, Cook RW, Buzaid AC.

J Surg Oncol. 2019 Jan;119(2):175-186. doi: 10.1002/jso.25319. Epub 2018 Dec 12. Review.

4.

Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years.

de Melo AC, Wainstein AJA, Buzaid AC, Thuler LCS.

Melanoma Res. 2018 Dec;28(6):629-636. doi: 10.1097/CMR.0000000000000511.

PMID:
30204684
5.

Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018.

Barbosa C Rocha F, Falcone AB, Buzaid AC, Pimenta JM, Schvartsman G, Frasson AL.

Breast Cancer Res Treat. 2018 Nov;172(2):265-272. doi: 10.1007/s10549-018-4912-x. Epub 2018 Aug 11. Review.

PMID:
30099633
6.

Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy.

de Almeida DVP, Gomes JR, Haddad FJ, Buzaid AC.

J Immunother. 2018 Sep;41(7):329-331. doi: 10.1097/CJI.0000000000000217.

PMID:
29461982
7.

Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.

Ribeiro Gomes J, Schmerling RA, Haddad CK, Racy DJ, Ferrigno R, Gil E, Zanuncio P, Buzaid AC.

J Immunother. 2016 Nov/Dec;39(9):367-372.

PMID:
27741091
8.

Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis.

da Rocha Lino A, Abrahão CM, Brandão RM, Gomes JR, Ferrian AM, Machado MC, Buzaid AC, Maluf FC, Peixoto RD.

J Gastrointest Oncol. 2015 Oct;6(5):511-5. doi: 10.3978/j.issn.2078-6891.2015.041.

9.

Algorithm for the management of metastatic cutaneous melanoma.

Buzaid AC, Agarwala SS, Hauschild A, Atkins M.

Chin Clin Oncol. 2014 Sep;3(3):32. doi: 10.3978/j.issn.2304-3865.2014.07.01.

10.

Systemic treatment of cutaneous and mucosal melanoma.

Agarwala SS, Guo J, Buzaid AC.

Chin Clin Oncol. 2014 Sep;3(3):25. doi: 10.3978/j.issn.2304-3865.2014.08.07. No abstract available.

11.

Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?

Bines J, Earl H, Buzaid AC, Saad ED.

Ann Oncol. 2014 Jun;25(6):1079-85. doi: 10.1093/annonc/mdu007. Epub 2014 Mar 13. Review.

PMID:
24625452
12.

Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.

Schutz FA, Buzaid AC, Sartor O.

Crit Rev Oncol Hematol. 2014 Sep;91(3):248-56. doi: 10.1016/j.critrevonc.2014.02.003. Epub 2014 Feb 15. Review.

PMID:
24613528
13.

Low-dose bevacizumab is effective in radiation-induced necrosis.

Alessandretti M, Buzaid AC, Brandão R, Brandão EP.

Case Rep Oncol. 2013 Dec 7;6(3):598-601. doi: 10.1159/000357401. eCollection 2013 Sep.

14.

Antitumor effects of electrochemical treatment.

Ciria HM, González MM, Zamora LO, Cabrales LE, Sierra González GV, de Oliveira LO, Zanella R, Buzaid AC, Parise O, Brito LM, Teixeira CA, Gomes Md, Moreno G, Feo da Veiga V, Telló M, Holandino C.

Chin J Cancer Res. 2013 Apr;25(2):223-34. doi: 10.3978/j.issn.1000-9604.2013.03.03.

15.

Cutaneous melanoma in Latin America: the need for more data.

Schmerling RA, Loria D, Cinat G, Ramos WE, Cardona AF, Sánchez JL, Martinez-Said H, Buzaid AC.

Rev Panam Salud Publica. 2011 Nov;30(5):431-8.

PMID:
22262269
16.

Identifying important breast cancer control strategies in Asia, Latin America and the Middle East/North Africa.

Bridges JF, Anderson BO, Buzaid AC, Jazieh AR, Niessen LW, Blauvelt BM, Buchanan DR.

BMC Health Serv Res. 2011 Sep 20;11:227. doi: 10.1186/1472-6963-11-227.

17.

High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy.

Buzaid AC, Schmerling RA, Vieira Guedes RA, de Freitas D, William WN Jr.

Melanoma Res. 2011 Aug;21(4):370-5. doi: 10.1097/CMR.0b013e32834710b5.

PMID:
21558968
18.

Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.

Buzaid AC, Mathias Cde C, Perazzo F, Simon SD, Fein L, Hidalgo J, Murad AM, Esser R, Senger S, Lerzo G.

Clin Colorectal Cancer. 2010 Dec;9(5):282-9. doi: 10.3816/CCC.2010.n.041.

PMID:
21208842
19.

Impact of [F-18] FDG-PET/CT in the restaging and management of patients with malignant melanoma.

Etchebehere EC, Romanato JS, Santos AO, Buzaid AC, Camargo EE.

Nucl Med Commun. 2010 Nov;31(11):925-30. doi: 10.1097/MNM.0b013e32833f6137.

PMID:
20856153
20.

Final version of 2009 AJCC melanoma staging and classification.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK.

J Clin Oncol. 2009 Dec 20;27(36):6199-206. doi: 10.1200/JCO.2009.23.4799. Epub 2009 Nov 16.

21.

A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.

Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY.

Melanoma Res. 2009 Feb;19(1):42-9. doi: 10.1097/CMR.0b013e328314b84a.

PMID:
19430405
22.

Peritonectomy for peritoneal carcinomatosis: long-term outcomes from a single Brazilian institution.

Akaishi E, Teixeira F, Katayama M, Mizumoto N, Costa FP, Buzaid AC, Hoff PM.

World J Surg. 2009 Apr;33(4):835-9; discussion 840. doi: 10.1007/s00268-008-9880-6.

PMID:
19169741
23.

Breast cancer in Latin America: results of the Latin American and Caribbean Society of Medical Oncology/Breast Cancer Research Foundation expert survey.

Cazap E, Buzaid AC, Garbino C, de la Garza J, Orlandi FJ, Schwartsmann G, Vallejos C, Guercovich A; Latin American and Caribbean Society of Medical Oncology.

Cancer. 2008 Oct 15;113(8 Suppl):2359-65. doi: 10.1002/cncr.23834.

24.

Exploring the role of novel agents in the treatment of renal cell carcinoma.

Maluf FC, Fernandes Gdos S, Kann AG, Aguilar-Ponce JL, de la Garza J, Buzaid AC.

Cancer Treat Rev. 2008 Dec;34(8):750-60. doi: 10.1016/j.ctrv.2008.07.002. Epub 2008 Sep 17. Review.

PMID:
18801619
25.

Electrochemical therapy to treat cancer (in vivo treatment).

Telló M, Oliveira L, Parise O, Buzaid AC, Oliveira RT, Zanella R, Cardona A.

Conf Proc IEEE Eng Med Biol Soc. 2007;2007:3524-7.

PMID:
18002757
26.
27.

Management of metastatic cutaneous melanoma.

Buzaid AC.

Oncology (Williston Park). 2004 Oct;18(11):1443-50; discussion 1457-9. Review.

28.

Acinar cell carcinoma of the pancreas.

Riechelmann RP, Hoff PM, Moron RA, da Câmera Lopes LH, Buzaid AC.

Int J Gastrointest Cancer. 2003;34(2-3):67-72.

PMID:
15361637
29.

An evidence-based staging system for cutaneous melanoma.

Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF.

CA Cancer J Clin. 2004 May-Jun;54(3):131-49; quiz 182-4. Review.

30.

Dendritic cell-tumor cell hybrid vaccination for metastatic cancer.

Barbuto JA, Ensina LF, Neves AR, Bergami-Santos P, Leite KR, Marques R, Costa F, Martins SC, Camara-Lopes LH, Buzaid AC.

Cancer Immunol Immunother. 2004 Dec;53(12):1111-8.

PMID:
15185011
31.

New TNM melanoma staging system: linking biology and natural history to clinical outcomes.

Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF.

Semin Surg Oncol. 2003;21(1):43-52. Review.

PMID:
12923915
32.

Biochemotherapy for advanced melanoma.

Buzaid AC.

Crit Rev Oncol Hematol. 2002 Oct;44(1):103-8. Review.

PMID:
12399002
33.

Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients.

Maranhão RC, Graziani SR, Yamaguchi N, Melo RF, Latrilha MC, Rodrigues DG, Couto RD, Schreier S, Buzaid AC.

Cancer Chemother Pharmacol. 2002 Jun;49(6):487-98. Epub 2002 Mar 21.

PMID:
12107554
34.

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS.

J Clin Oncol. 2002 Apr 15;20(8):2045-52.

PMID:
11956264
35.

Practical guidelines for the management of biochemotherapy-related toxicity in melanoma.

Buzaid AC, Atkins M.

Clin Cancer Res. 2001 Sep;7(9):2611-9. Review.

36.

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF.

J Clin Oncol. 2001 Aug 15;19(16):3635-48. Review.

PMID:
11504745
37.

Classification and staging of melanoma.

Gershenwald JE, Buzaid AC, Ross MI.

Clin Lab Med. 2000 Dec;20(4):785-815. Review.

PMID:
11221515
38.

Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival.

Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA.

Clin Cancer Res. 2000 Dec;6(12):4768-75.

39.

The changing prognosis of melanoma.

Buzaid AC, Anderson CM.

Curr Oncol Rep. 2000 Jul;2(4):322-8. Review.

PMID:
11122860
40.

Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.

Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC.

Clin Cancer Res. 2000 Oct;6(10):3895-903.

41.

Clinical classification and staging.

Gershenwald JE, Fischer D, Buzaid AC.

Clin Plast Surg. 2000 Jul;27(3):361-76, viii. Review.

PMID:
10941558
42.

Strategies for combining chemotherapy and biotherapy in melanoma.

Buzaid AC.

Cancer Control. 2000 Mar-Apr;7(2):185-97. Review. No abstract available.

PMID:
10783824
43.

A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy.

Eton O, Buzaid AC, Bedikian AY, Smith TM, Papadopoulos NE, Ellerhorst JA, Hibberts JL, Legha SS, Benjamin RS.

Cancer. 2000 Apr 1;88(7):1703-9.

PMID:
10738230
44.

A new American Joint Committee on Cancer staging system for cutaneous melanoma.

Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Houghton A Jr, Kirkwood JM, Mihm MF, Morton DL, Reintgen D, Ross MI, Sober A, Soong SJ, Thompson JA, Thompson JF, Gershenwald JE, McMasters KM.

Cancer. 2000 Mar 15;88(6):1484-91.

PMID:
10717634
45.

Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases.

Eton O, East M, Legha SS, Bedikian A, Buzaid AC, Papadopoulos N, Hodges C, Gianan M, Carrasco CH, Benjamin RS.

Melanoma Res. 1999 Oct;9(5):483-9.

PMID:
10596915
46.

Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.

Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, Brown J, Fischer D, Bolognia J, Buzaid AC.

Cancer. 1999 Dec 1;86(11):2252-8.

PMID:
10590365
47.

Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma.

Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Plager C, McIntyre S, Viallet J.

Anticancer Drugs. 1999 Sep;10(8):735-9.

PMID:
10573206
48.

Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10.

Ekmekcioglu S, Okcu MF, Colome-Grimmer MI, Owen-Schaub L, Buzaid AC, Grimm EA.

Melanoma Res. 1999 Jun;9(3):261-72.

PMID:
10465582
49.

Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.

Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS.

Oncol Rep. 1999 Sep-Oct;6(5):1097-9.

PMID:
10425308
50.

Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases.

Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, Plager C, Ross M, Lee JE, Mansfield P, Rice J, Ring S, Lee JJ, Strom E, Benjamin R.

Melanoma Res. 1998 Dec;8(6):549-56.

PMID:
9918417

Supplemental Content

Loading ...
Support Center